Communication Download Insurance Coverage and Processing 
Pharmaceutical Technology
JUNE 6, 2025
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Pharmaceutical Technology
NOVEMBER 30, 2022
In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Medicare Part A, Part B, and Part D do not generally cover approved weight loss medications like Saxenda, but Medicare Advantage plans may allow for expanded coverage, as per the Medicare.org site. By GlobalData. United Kingdom.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 30, 2022
In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Medicare Part A, Part B, and Part D do not generally cover approved weight loss medications like Saxenda, but Medicare Advantage plans may allow for expanded coverage, as per the Medicare.org site. By GlobalData. United Kingdom.
Pharmaceutical Technology
JUNE 12, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. We may still continue to send you service-related and other non-promotional communications. Topic sponsors are not involved in the creation of editorial content.
pharmaphorum
OCTOBER 7, 2021
Unlike the abundance of freely downloadable wellbeing apps, DTx products are meant to be prescribed for a therapeutic indication and potentially eligible for reimbursement by national health services subject to health technology assessment studies. Contact: Antonietta Pannella, Marketing & Communications Director, Healthware Group.
The Thyroid Pharmacist
AUGUST 4, 2023
4] One of the key things to note is that this gene variation also prevents people from properly methylating, which is one of the body’s key detox processes that helps them get rid of toxins. However, some may be concerned with this genetic information getting reported on insurance or to employers.
Pharmaceutical Technology
FEBRUARY 7, 2023
Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. Meanwhile, in Germany, the AMNOG process is conducted twelve months after the drug is launched, thus giving freedom to the company to set the drug’s price during this period.
Expert insights. Personalized for you.
81 
Let's personalize your content